Harbin Pharmaceutical Group Co., Ltd. (600664.SH) Latest Company News

Oct 26, 2026, 09:12 UTC
Harbin Pharmaceutical Group reported revenue of 12.352 billion yuan and net profit attributable to shareholders of 600 million yuan for the first three quarters of 2026.
Source:
- finance.sina.cn
Oct 26, 2026, 09:12 UTC
Harbin Pharmaceutical Group reported third-quarter 2026 revenue of 4.057 billion yuan, up 4.11% year over year, and net profit attributable to shareholders of 190 million yuan, up 175.67%.
Source:
- finance.sina.cn
Oct 12, 2026, 07:49 UTC
China’s National Medical Products Administration approved Harbin Pharmaceutical Group Bioengineering Co.’s sodium sulfate active pharmaceutical ingredient application, changing its registration status to “A.”
Source:
- finance.sina.cn
Oct 11, 2026, 08:07 UTC
Harbin Pharmaceutical Group announced that its director and president, Lu Chuanyou, had received a case-filing notice and a detention notice from a supervisory commission.
Source:
- finance.sina.cn
Sep 21, 2026, 09:58 UTC
China's A-share major indices closed higher on September 21, 2026, with the Shanghai Composite up 0.97% at 3949.91, the Shenzhen Component up 0.65% at 13730.02, and the ChiNext up 0.80% at 3399.59, as over 4,500 stocks advanced and innovative drug concept stocks surged.
Source:
- news.cnfol.com
- m.21jingji.com
Aug 25, 2026, 08:59 UTC
Harbin Pharmaceutical Group announced its first-half 2026 results: net profit attributable to shareholders of 410 million yuan, up 57.99% year-on-year.
Source:
- finance.sina.cn
Aug 3, 2026, 09:41 UTC
Harbin Pharmaceutical announced that its subsidiaries Harbin General Factory and Harbin No.6 Factory have two products provisionally selected in the 12th national centralized drug procurement, with the procurement period lasting until December 31, 2029.
Source:
- finance.sina.cn
Aug 2, 2026, 05:48 UTC
In July 2026, oil and gas extraction and innovative drug concept stocks rose against the market, with Harbin Pharmaceutical up 96.99% and Longshengongfa up 93.93% in the innovative drug sector, and Keli Co. up 56.82% and Tongyuan Petroleum up 49.13% in the oil and gas extraction sector.
Source:
- wap.eastmoney.com
Jul 29, 2026, 07:33 UTC
Harbin Pharmaceutical's subsidiary Harbin Bio received an approval notice from China's National Medical Products Administration for the marketing application of potassium sulfate active pharmaceutical ingredient.
Source:
- finance.sina.cn
Jul 13, 2026, 10:17 UTC
China's National Health Commission and other departments released the 2026 edition of the National Essential Medicines List, effective September 1, 2026, which includes 118 specifications from Harbin Pharmaceutical Group and its subsidiaries, with 6 new varieties added and 1 variety removed.
Source:
- finance.sina.cn

600664.SH

Harbin Pharmaceutical Group reported revenue of 12.352 billion yuan and net profit attributable to shareholders of 600 million yuan for the first three quarters of 2026.

Harbin Pharmaceutical Group reported third-quarter 2026 revenue of 4.057 billion yuan, up 4.11% year over year, and net profit attributable to shareholders of 190 million yuan, up 175.67%.

China’s National Medical Products Administration approved Harbin Pharmaceutical Group Bioengineering Co.’s sodium sulfate active pharmaceutical ingredient application, changing its registration status to “A.”

Harbin Pharmaceutical Group announced that its director and president, Lu Chuanyou, had received a case-filing notice and a detention notice from a supervisory commission.

China's A-share major indices closed higher on September 21, 2026, with the Shanghai Composite up 0.97% at 3949.91, the Shenzhen Component up 0.65% at 13730.02, and the ChiNext up 0.80% at 3399.59, as over 4,500 stocks advanced and innovative drug concept stocks surged.

Harbin Pharmaceutical Group announced its first-half 2026 results: net profit attributable to shareholders of 410 million yuan, up 57.99% year-on-year.

Harbin Pharmaceutical announced that its subsidiaries Harbin General Factory and Harbin No.6 Factory have two products provisionally selected in the 12th national centralized drug procurement, with the procurement period lasting until December 31, 2029.

In July 2026, oil and gas extraction and innovative drug concept stocks rose against the market, with Harbin Pharmaceutical up 96.99% and Longshengongfa up 93.93% in the innovative drug sector, and Keli Co. up 56.82% and Tongyuan Petroleum up 49.13% in the oil and gas extraction sector.

Harbin Pharmaceutical's subsidiary Harbin Bio received an approval notice from China's National Medical Products Administration for the marketing application of potassium sulfate active pharmaceutical ingredient.

China's National Health Commission and other departments released the 2026 edition of the National Essential Medicines List, effective September 1, 2026, which includes 118 specifications from Harbin Pharmaceutical Group and its subsidiaries, with 6 new varieties added and 1 variety removed.